Protective Effects of Citronellol Against Rhabdomyolysis-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB and IL-1β

Authors

  • Yasmeen Nasrawi Ministry of Health and Environment, Karbala Health Directorate
  • Sermad Hashim Kadhim 2Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.31351/vol32issSuppl.pp85-90

Abstract

Objectives: acute kidney injury (AKI) is a serious pathophysiology side effect of rhabdomyolysis. Inflammatory mechanisms play a role in the development of rhabdomyolysis-induced AKI. Citronellol (CT) is a naturally occurring monoterpene alcohol (3,7-Dimethyl-6-often-1-ol) found in aromatic plant species' essential oils. In this study, we explored the protective effects of Citronellol on glycerol-induced AKI.

Methods: Four groups of eight mice each (n=8) were formed by randomly dividing the animals into the groups, glycerol-induced AKI model group, low-dose CT-treated group (50mg/kg), high-dose CT-treated group (100mg/kg), and control group. The renal functions of mice from all groups were evaluated using serum urea and creatinine. Creatine kinase (CK) level was used to detect rhabdomyolysis. Inflammatory response was determined using Nf-kB and iL-1B levels.

Results: Citronellol in both doses 50&100 mg/kg significantly decreased serum urea, creatinine and CK as Compared to the glycerol group, as well as treatment with citronellol resulted in a lower expression of both NF-κB and IL-1β in the renal tissue, indicating that citronellol may have an anti-inflammatory effect in AKI.

Conclusion: prophylaxis with low and high doses of citronellol improved inflammatory responses and renal function. It's possible that by inhibiting Nf-kB and iL-1B, these positive effects were achieved, inhibiting the development of inflammatory cytokines as a result. These discoveries reveal fresh details regarding a potential treatment option for kidney injury caused by rhabdomyolysis.

References

Kodadek L, Carmichael SP, Seshadri A, Pathak A, Hoth J, Appelbaum R, Michetti CP, Gonzalez RP. Rhabdomyolysis: an American association for the surgery of trauma critical care committee clinical consensus document. Trauma Surgery & Acute Care Open. 2022 Jan 1;7(1):e000836.

Cabral BM, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Disease-a-Month. 2020 Aug 1;66(8):101015.

Yang SY, Chiou TT, Shiao CC, Lin HY, Chan MJ, Wu CH, Sun CY, Wang WJ, Huang YT, Wu VC, Chen YC. Nomenclature and diagnostic criteria for acute kidney injury–2020 consensus of the Taiwan AKI-task force. Journal of the Formosan Medical Association. 2022 Apr 1;121(4):749-65.

Treacy O, Brown NN, Dimeski G. Biochemical evaluation of kidney disease. Translational andrology and urology. 2019 May;8(Suppl 2):S214.

Cabral BM, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Disease-a-Month. 2020 Aug 1;66(8):101015.

Abd-Ellatif RN, Hegab II, Atef MM, Sadek MT, Hafez YM. Diacerein protects against glycerol-induced acute kidney injury: modulating oxidative stress, inflammation, apoptosis and necroptosis. Chemico-biological interactions. 2019 Jun 1;306:47-53.

Chang SN, Haroon M, Dey DK, Kang SC. Rhabdomyolysis-induced acute kidney injury and concomitant apoptosis induction via ROS-mediated ER stress is efficaciously counteracted by epigallocatechin gallate. The Journal of Nutritional Biochemistry. 2022 Dec 1;110:109134.

Downloads

Published

2023-11-01